Acquiring Company
Halozyme Therapeutics
Acquired Company
Elektrofi
San DiegoManufacturingBiotechnologyHealth CarePharmaceuticalBiopharmaDescription
Halozyme Therapeutics has successfully completed its acquisition of Elektrofi, a biopharmaceutical firm, for an upfront payment of $750 million, with additional milestone payments. The merger aims to enhance Halozyme's drug delivery technology portfolio with Elektrofi's Hypercon™ formulation technology. This strategic acquisition is expected to drive long-term royalty growth and improve patient treatment experiences.
Quick answer
Halozyme Therapeutics is acquiring Elektrofi for $750 million, announced November 18, 2025. Halozyme Therapeutics is based in San Diego, California, United States.
- How much did Halozyme Therapeutics pay for Elektrofi?
- The reported deal value is $750 million.
- What does Halozyme Therapeutics do?
- Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.
- Where are Halozyme Therapeutics and Elektrofi based?
- Halozyme Therapeutics is based in San Diego, California, United States.
- Who are the decision-makers at Halozyme Therapeutics?
- Fundz holds 3 contacts at Halozyme Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Biopharma
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie acquires Bretisilocin for mental health expansion (October 15, 2025)
- Sanofi acquires Dynavax Technologies for $15.50/share (December 24, 2025)
- SAI Parenterals acquires majority stake in Noumed (December 5, 2025)
- Day One to acquire Mersana for $130 million, $130M (November 30, 2025)
- XOMA Royalty acquires LAVA Therapeutics N.V. (November 21, 2025)
- Pfizer to acquire Metsera for $10 billion, $10B (November 15, 2025)
Who to call at Halozyme Therapeutics, and when
When Halozyme Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Halozyme Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Halozyme Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Halozyme Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Halozyme Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Elektrofi?
Elektrofi was acquired by Halozyme Therapeutics, based in San Diego. The deal was reported on November 18, 2025. Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. Halozyme Therapeutics is publicly traded (HALO) and operates in Manufacturing.
When did Halozyme Therapeutics acquire Elektrofi?
Halozyme Therapeutics's acquisition of Elektrofi was reported on November 18, 2025. Halozyme Therapeutics has successfully completed its acquisition of Elektrofi, a biopharmaceutical firm, for an upfront payment of $750 million, with additional milestone payments. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Elektrofi do?
Elektrofi is the company acquired in this transaction. It is privately held.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.